<style face="normal" font="default" size="100%">214 The KRAS<sup>G12D</sup>(ON) covalent tricomplex inhibitor RM-044 increases tumor antigen presentation and TCR repertoire diversity to promote anti-tumor immunity in a preclinical model of KRAS<sup>G12D</sup> mutant cancer</style>

Drupal-HighWire